MCID: LCH002
MIFTS: 54

Lichen Planus

Categories: Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lichen Planus

MalaCards integrated aliases for Lichen Planus:

Name: Lichen Planus 12 74 36 54 43 15 17 71 32
Lichen, Ruber Planus 12
Lichen Ruber Planus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9201
KEGG 36 H01654
ICD9CM 34 697.0
MeSH 43 D008010
NCIt 49 C3189
SNOMED-CT 67 4776004
ICD10 32 L43 L43.9
UMLS 71 C0023646

Summaries for Lichen Planus

KEGG : 36 Lichen planus (LP) is a chronic inflammatory and immune mediated skin disease with characteristic clinical and histopathologic features. The skin and oral mucosa are the most frequently involved areas. Other mucous membranes (including the genitalia, esophagus, and conjunctiva) and skin appendages (e.g., scalp hair and nails) can also be affected. The etiology and pathogenesis of LP remain unclear. An autoimmune reaction in which CD8+-T lymphocytes attack basal keratinocytes leading to apoptosis of the cells has been favored. Various potential triggers, e.g. viral or bacterial antigens, metal ions, drugs or physical factors, could initiate the autoimmune process. Nonetheless, the role of the individual trigger factors is controversial. There is a significant association between lichen planus and infection with hepatitis C virus (HCV). The diagnosis of LP is based on the clinical presentation and should be confirmed by biopsy, if suspected. Histopathology is often conclusive, but in vesiculobullous cutaneous LP or erosive oral LP, direct immunofluorescence (DIF) studies can be an integral step in differentiating between LP and other diseases. With few exceptions, all forms of LP are treated with the same measures. Depending on the severity of the findings, topical and systemic treatment options are available.

MalaCards based summary : Lichen Planus, also known as lichen, ruber planus, is related to lichen planus pemphigoides and graft-versus-host disease, and has symptoms including pruritus An important gene associated with Lichen Planus is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are Developmental Biology and Toll-like Receptor Signaling Pathway. The drugs Tacrolimus and Pimecrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and t cells, and related phenotype is Increased gamma-H2AX phosphorylation.

Disease Ontology : 12 A lichen disease that is located in skin, located in tongue or located in oral mucosa, which presents itself in the form of papules, lesions or rashes.

Wikipedia : 74 Lichen planus is a chronic inflammatory and immune mediated disease that affects the skin, nails, hair,... more...

Related Diseases for Lichen Planus

Diseases in the Lichen Planus family:

Lichen Planus, Familial Rare Lichen Planus

Diseases related to Lichen Planus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 782)
# Related Disease Score Top Affiliating Genes
1 lichen planus pemphigoides 35.4 DST COL17A1
2 graft-versus-host disease 31.8 TNF IL6 IFNG GZMB
3 leukoplakia 31.8 KRT13 KRT1 DEFB4A
4 exanthem 31.7 TNF IL6 CXCL8
5 candidiasis 31.6 TNF IL6 IFNG DEFB4A CXCL8
6 herpes zoster 31.5 TNF IFNG COL17A1
7 stomatitis 31.5 TNF MX1 IL6 IFNG CXCL8
8 hepatitis b 31.4 TNF MX1 IL6 IFNG CXCL8
9 viral hepatitis 31.4 TNF MX1 IL6 IFNG
10 aphthous stomatitis 31.4 TNF IL6 IFNG CXCL8
11 colitis 31.4 TNF IL6 IFNG CXCL8
12 chickenpox 31.4 TNF IL6 IFNG
13 pemphigus 31.4 TNF DST DSG3 COL17A1
14 ulcerative colitis 31.3 TNF IL6 IFNG ICAM1 CXCL8
15 gingivitis 31.3 TNF IL6 IFNG ICAM1 DEFB4A CXCL8
16 esophagitis 31.3 TNF IVL IL6 CXCL8
17 keratoconjunctivitis 31.3 TNF IL6 IFNG ICAM1 CXCL8
18 rosacea 31.2 TNF IL6 CXCL8
19 keratosis 31.2 KRT10 KRT1 IVL FLG DST
20 crohn's disease 31.2 TNF IL6 IFNG CXCL8
21 cryoglobulinemia 31.2 TNF IL6 IFNG CXCR3
22 allergic hypersensitivity disease 31.2 TNF IFNG ICAM1 FLG CXCL8
23 bullous pemphigoid 31.2 IVL DST DSG3 CXCL8 COL17A1
24 vaginitis 31.1 TNF IL6 DEFB4A CXCL8
25 paraneoplastic pemphigus 31.1 DST DSG3 COL17A1
26 seborrheic dermatitis 31.1 TNF FLG CXCL8
27 chronic conjunctivitis 31.1 TNF IL6 CXCL8
28 linear iga disease 31.1 DST COL17A1
29 gastritis 31.0 TNF IL6 DEFB4A CXCL8
30 sclerosing cholangitis 31.0 TNF IL6 CXCL8
31 periodontitis 31.0 TNF IL6 IFNG ICAM1 DEFB4A CXCL8
32 amebiasis 31.0 TNF ICAM1 CXCL8
33 neurofibromatosis, type ii 31.0 TNF IL6 DEFB4A CXCL8
34 erythema multiforme 31.0 TNF IL6 IFNG ICAM1 GZMB CXCR3
35 proteasome-associated autoinflammatory syndrome 1 31.0 TNF IL6 IFNG ICAM1 CXCL8
36 guttate psoriasis 31.0 ITGAL IFNG
37 pericarditis 30.9 TNF IL6 IFNG CXCL8
38 keratitis, hereditary 30.9 TNF IL6 CXCL9 CXCL8
39 autoimmune disease 30.9 TNF ITGAL IL6 IFNG DSG3 CXCR3
40 peptic ulcer disease 30.9 TNF DEFB4A CXCL8
41 atrophic gastritis 30.9 TNF IL6 CXCL8
42 pemphigus vulgaris, familial 30.8 IVL DST DSG3 COL17A1
43 conjunctivitis 30.8 TNF IL6 IFNG ICAM1 CXCL9 CXCL8
44 crohn's colitis 30.8 TNF IFNG CXCL8
45 blepharitis 30.8 TNF IL6 CXCL8
46 poliomyelitis 30.8 TNF IFNG ICAM1
47 diarrhea 30.8 TNF IL6 IFNG CXCL8
48 adult-onset still's disease 30.8 TNF IL6 CXCL8
49 arthritis 30.8 TNF IL6 IFNG ICAM1 CXCL8
50 acute cystitis 30.8 TNF IL6 CXCL8

Graphical network of the top 20 diseases related to Lichen Planus:



Diseases related to Lichen Planus

Symptoms & Phenotypes for Lichen Planus

UMLS symptoms related to Lichen Planus:


pruritus

GenomeRNAi Phenotypes related to Lichen Planus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased gamma-H2AX phosphorylation GR00053-A 9.28 COL17A1 CXCL9 CXCR3 DEFB4A DSG3 IVL

Drugs & Therapeutics for Lichen Planus

Drugs for Lichen Planus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4 Lycopene Approved, Investigational Phase 4 502-65-8 53477748
5
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Chitosan Experimental Phase 4 9012-76-4 71853
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
15
Pomegranate Experimental, Investigational Phase 4
16 Hormone Antagonists Phase 4
17 Anti-Inflammatory Agents Phase 4
18 glucocorticoids Phase 4
19 Hormones Phase 4
20 Calcineurin Inhibitors Phase 4
21 Analgesics Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Dermatologic Agents Phase 4
25 Antirheumatic Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Respiratory System Agents Phase 4
28 Betamethasone benzoate Phase 4
29 Betamethasone Valerate Phase 4 2152-44-5
30 Betamethasone sodium phosphate Phase 4
31 Betamethasone-17,21-dipropionate Phase 4
32 Protective Agents Phase 4
33 Radiation-Protective Agents Phase 4
34 Methylprednisolone Acetate Phase 4
35 Neuroprotective Agents Phase 4
36 Chlorhexidine gluconate Phase 4
37 Anesthetics, Local Phase 4
38 Anesthetics Phase 4
39 Central Nervous System Depressants Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Sodium Channel Blockers Phase 4
42 Diuretics, Potassium Sparing Phase 4
43
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
44
Aminolevulinic acid Approved Phase 2, Phase 3 106-60-5 137
45
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
46
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
47
Terbinafine Approved, Investigational, Vet_approved Phase 3 91161-71-6 5402 1549008
48
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
49
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
50
Petrolatum Approved, Investigational Phase 3 8009-03-8

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial Completed NCT02858297 Phase 4 Glucosamine sulfate;triamcinolone acetonide
2 Comparative Study of the Efficacy of Lycopene Versus Prednisolone in the Management of Oral Lichen Planus: A Randomized, Double Blind Clinical Trial Completed NCT02587117 Phase 4 lycopene;Prednisolone
3 A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus Completed NCT02443311 Phase 4 Pimecrolimus 1% cream;Betamethasone 17-valerate 0.1% cream
4 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
5 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
6 Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Active, not recruiting NCT04193748 Phase 4 Topical pomegranate seeds and peel extracts
7 Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome Withdrawn NCT02690844 Phase 4 Clonazepam mixed with Mucolox®;Mucolox® alone;Clonazepam
8 A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP) Unknown status NCT01282515 Phase 2, Phase 3 clobetasolpropionate;hexaminolevulinate
9 The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial Unknown status NCT01083420 Phase 3 Minocycline;Dexamethasone
10 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
11 Randomized Placebo-Controlled Clinical Pilot Trial Regarding the Efficacy of Elidel Cream on Erosive Oral Lichen Planus Completed NCT00130572 Phase 3 Pimecrolimus
12 Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus Completed NCT02329600 Phase 3 green tea tablets (Green tea extract 5:1) 200 mg;Triamcinolone Acetonide
13 Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treatment Oral LichenPlanus Completed NCT02421770 Phase 3
14 Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids Terminated NCT01061853 Phase 3 TOPICAL SIROLIMUS (RAPAMUNE*);TOPICAL BETAMETHASONE 0.05%
15 A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus Unknown status NCT01524744 Phase 2 Pimecrolimus ointment;Adcortyl
16 An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Unknown status NCT01041625 Phase 2 Apremilast (CC-10004)
17 Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus. Unknown status NCT01538732 Phase 2 alitretinoin
18 Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial Unknown status NCT03293368 Phase 2 Triamcinolone Acetonide
19 Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial Completed NCT01974414 Phase 1, Phase 2 orally administered cedar honey
20 Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus- A Double-blinded Randomized Clinical Trial in Sri Lanka Completed NCT02744378 Phase 2 Tacrolimus 0.1%;Clobetasol 0.05%
21 Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Completed NCT00484250 Phase 2 metronidazole,doxycycline
22 Efficacy of Oral Lycopene in the Management of Oral Lichen Planus Completed NCT00656214 Phase 2 Lycopene;Placebo
23 A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus Completed NCT00297037 Phase 2 Pimecrolimus 1% cream
24 A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus Completed NCT00525421 Phase 2 Curcuminoids;Placebo
25 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study Completed NCT02106468 Phase 2 Prednisone tablet 5mg;Omega-3 soft capsules 1000 mg
26 Treatment of Oral Lichen Planus Lesions Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
27 Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus Completed NCT00102557 Phase 2 Hydroxychloroquine
28 Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus Completed NCT00111072 Phase 2 dexamethasone 0.01% solution
29 Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues Completed NCT02920658 Phase 2 NAVS Naphthalan;0.05% Betamethasone dipropionate
30 Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus Completed NCT02453503 Phase 2 Licorice;Triamcinolone Acetonide
31 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
32 Valchlor in the Treatment of Lichen Planopilaris: A Single Arm, Open‐ Label, Exploratory Study Completed NCT03417141 Phase 2 Valchlor
33 A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome Completed NCT01064830 Phase 2 topical cyclosporine ophthalmic suspension 0.05%;vehicle
34 A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus Recruiting NCT03026478 Phase 2 Betamethasone Dipropionate;Clobetasol Propionate
35 The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus Recruiting NCT03656666 Phase 2 Apremilast;Placebo
36 KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus Recruiting NCT03858634 Phase 2 KPL-716;Placebo
37 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus Recruiting NCT02850601 Phase 2 Dexamethasone
38 INCB018424 in the Treatment of Cutaneous Lichen Planus Recruiting NCT03697460 Phase 2 INCB018424
39 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate When Administered Intra-orally Twice Daily in Patients With Oral Lichen Planus (OLP) Using Rivelin®-CLO Patches Recruiting NCT03592342 Phase 2 Clobetasol Propionate
40 Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) Recruiting NCT03395340 Phase 2 Ruxolitinib 1.5% cream;Vehicle cream
41 Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus Active, not recruiting NCT03386643 Phase 2 Bifidobacterium animalis subsp. lactis HN019;Clobetasol propionate 0.05%
42 TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN Active, not recruiting NCT04128722 Phase 2 Sirolimus Oral Liquid Product 1mg/mL
43 The APOLP Trial: A Single-Center, Randomized, 16 Weeks, Explanatory, Parallel-Group, Superiority, Blinded, Placebo-Controlled, Clinical Trial of Apremilast Use in Oral Lichen Planus Not yet recruiting NCT03836885 Phase 2 Apremilast;Placebo
44 Use of Topical Non-Steroidal Anti- Inflammatory to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. Not yet recruiting NCT03509675 Phase 2 Non-Steroidal Anti-inflammatory Topical Rinse;Placebos
45 A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus Terminated NCT00226174 Phase 2 Curcuminoids
46 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus Terminated NCT00135733 Phase 2 Amevive (Alefacept);Placebo
47 Phase 2 Study of the Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream: a Double Blind Randomized Prospective Trial With Measurement of Pimecrolimus Levels in the Blood Terminated NCT00321750 Phase 2 1% pimecrolimus cream
48 A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus Terminated NCT00285779 Phase 2 Etanercept;Placebo
49 Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Oral Mucosal Pain in Burning Mouth Syndrome, Sjögrens Syndrome and Lichen Planus. Terminated NCT01584947 Phase 2 Bupivacaine;Placebo
50 Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus Unknown status NCT01375101 Phase 1 placebo;Quercetin

Search NIH Clinical Center for Lichen Planus

Cochrane evidence based reviews: lichen planus

Genetic Tests for Lichen Planus

Anatomical Context for Lichen Planus

The Foundational Model of Anatomy Ontology organs/tissues related to Lichen Planus:

19
Skin, Tongue

MalaCards organs/tissues related to Lichen Planus:

40
Skin, T Cells, Tongue, Liver, Thyroid, Testes, Lung

Publications for Lichen Planus

Articles related to Lichen Planus:

(show top 50) (show all 7466)
# Title Authors PMID Year
1
T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. 54 61
19686329 2010
2
Involvement of granzyme B and granulysin in the cytotoxic response in lichen planus. 54 61
18331568 2008
3
The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication. 54 61
18231758 2007
4
Cytokine alterations in lichen sclerosus: an immunohistochemical study. 54 61
17034521 2006
5
Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. 54 61
16197389 2005
6
Cytotoxic molecule expression and epithelial cell apoptosis in oral and cutaneous lichen planus. 54 61
15151217 2004
7
Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. 54 61
12705750 2003
8
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. 54 61
12373334 2002
9
Oral lichen planus: an update. 54 61
12582419 2002
10
Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. an immunohistochemical study. 54 61
12389997 2002
11
Topical retinaldehyde treatment in oral lichen planus and leukoplakia. 54 61
12779246 2002
12
Identification of the AgNORs, PCNA and ck16 proteins in oral lichen planus lesions. 54 61
11834097 2001
13
Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. 54 61
11694869 2001
14
Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. 54 61
11523046 2001
15
Lichen planus exacerbation by interferon-alpha-2A for chronic viral hepatitis C. 54 61
19864712 2000
16
Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? 54 61
10815859 2000
17
Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma. 54 61
10494726 1999
18
Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. 54 61
10417629 1999
19
Acquired skin disease of hemidesmosomes. 54 61
10379705 1999
20
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 54 61
10233762 1999
21
BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. 54 61
10335914 1999
22
C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. 54 61
10027407 1999
23
MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. 54 61
9856808 1998
24
Keratin and involucrin expression in discoid lupus erythematosus and lichen planus. 54 61
9341972 1997
25
The role of granzyme B-expressing CD8-positive T cells in apoptosis of keratinocytes in lichen planus. 54 61
9341973 1997
26
Altered distribution and synthesis of laminin-5 (kalinin) in oral lichen planus, epithelial dysplasias and squamous cell carcinomas. 54 61
9115910 1997
27
Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. 54 61
8864684 1996
28
Vascular adhesion molecules in oral lichen planus. 54 61
8784900 1996
29
In three types of interface dermatitis, different patterns of expression of intercellular adhesion molecule-1 (ICAM-1) indicate different triggers of disease. 54 61
7616001 1995
30
Destruction of the epithelial anchoring system in lichen planus. 54 61
7615961 1995
31
Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. 54 61
7600144 1995
32
Alteration of cytokeratin expression in oral lichen planus. 54 61
7542150 1995
33
Expression of MxA protein in inflammatory dermatoses. 54 61
7822763 1995
34
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques. 54 61
7538409 1994
35
Immunofluorescent analysis of the basement membrane zone in lichen planus suggests destruction of the lamina lucida in bullous lesions. 54 61
8040461 1994
36
Increased submucosal factor XIIIa-positive dendrocytes in oral lichen planus. 54 61
7517451 1994
37
Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. 54 61
8100122 1993
38
Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of beta 2-integrins. 54 61
1401271 1992
39
Expression of the CD54 (ICAM-1) and CD11a (LFA-1) adhesion molecules in oral mucosal inflammation. 54 61
1348286 1992
40
Elastolysis in lichen ruber planus. 54 61
1681662 1991
41
Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. 54 61
2258627 1990
42
[Lichen planus: etiopathogenesis]. 54 61
1983174 1990
43
Induction and upregulation of adhesion receptors in oral and dermal lichen planus. 54 61
1981078 1990
44
Lichen planus pemphigoides: case report and results of immunofluorescence and immunoelectron microscopic study. 54 61
2180994 1990
45
Etretinate suppresses ICAM-1 expression by lesional keratinocytes in healing cutaneous lichen planus. 54 61
1979727 1990
46
Immunohistochemical studies on fibrillin in amyloidosis, lichen ruber planus and porphyria. 54 61
1699374 1990
47
Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. 61
31589773 2020
48
Update on treatments for erosive vulvovaginal lichen planus. 61
31631346 2020
49
Evidence for a significant role of B-cells in the pathogenesis of oral lichen planus: Preliminary results of a cross-sectional study. 61
31868240 2020
50
[Efficacy of photopheresis in the treatment of erosive lichen planus: A retrospective study]. 61
31230777 2020

Variations for Lichen Planus

Expression for Lichen Planus

Search GEO for disease gene expression data for Lichen Planus.

Pathways for Lichen Planus

Pathways related to Lichen Planus according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 TNF KRT16 KRT13 KRT10 KRT1 IVL
2
Show member pathways
13.11 TNF MX1 IL6 IFNG CXCL9 CXCL8
3
Show member pathways
12.75 TNF MX1 ITGAL IL6 IFNG ICAM1
4
Show member pathways
12.71 TNF ITGAL IL6 IFNG ICAM1 GZMB
5
Show member pathways
12.51 TNF ITGAL IFNG ICAM1 GZMB
6 12.33 TNF ITGAL IL6 ICAM1
7
Show member pathways
12.32 TNF IL6 IFNG ICAM1
8
Show member pathways
12.32 KRT16 KRT13 KRT10 KRT1 IVL FLG
9
Show member pathways
12.31 TNF IL6 IFNG DEFB4A CXCL8
10
Show member pathways
12.3 TNF IL6 IFNG CXCL8
11
Show member pathways
12.3 TNF IL6 CXCR3 CXCL9 CXCL8
12
Show member pathways
12.26 TNF MX1 IL6 IFNG CXCL8
13 12.23 TNF IL6 DEFB4A CXCL8
14
Show member pathways
12.13 TNF IL6 IFNG DEFB4A CXCL8
15 11.98 TNF ITGAL IL6 IFNG
16 11.97 TNF IL6 ICAM1 CXCL8
17
Show member pathways
11.93 KRT16 KRT13 KRT1 DST
18 11.91 TNF IL6 IFNG ICAM1 CXCL8
19 11.9 TNF IL6 IFNG CXCL8
20 11.88 TNF IL6 ICAM1 CXCL8
21 11.78 IL6 IFNG CXCL8
22 11.77 IL6 IFNG ICAM1 CXCL8
23 11.75 TNF IL6 CXCL8
24
Show member pathways
11.75 TNF IFNG CXCL8
25 11.74 TNF IL6 IFNG
26 11.74 TNF IFNG GZMB CXCR3
27 11.68 TNF IL6 IFNG CXCL9
28 11.65 TNF IL6 CXCL8
29
Show member pathways
11.64 TNF IFNG GZMB
30 11.62 KRT16 KRT13 KRT10 ITGAL ICAM1 DEFB4A
31 11.6 TNF IL6 CXCL8
32 11.58 IL6 IFNG CXCL8
33 11.55 TNF IL6 IFNG
34 11.52 TNF IL6 ICAM1
35 11.48 TNF IL6 IFNG
36 11.47 TNF IL6 ICAM1 CXCL8
37
Show member pathways
11.45 TNF IL6 IFNG ICAM1 CXCL8
38 11.4 ITGAL IFNG ICAM1 CXCL8
39 11.4 TNF ITGAL IL6 IFNG ICAM1 CXCL8
40 11.39 IFNG ICAM1 CXCL9
41 11.34 IVL IL6 CXCL8
42 11.34 ITGAL CXCR3 CXCL9
43 11.3 TNF IL6 IFNG
44 11.27 TNF IL6 IFNG ICAM1
45 11.24 TNF IL6 IFNG
46 11.02 TNF ITGAL IL6 CXCL9 CXCL8 COL17A1
47 11 TNF IL6 CXCL8
48 10.8 TNF ITGAL IL6 IFNG ICAM1 CXCL8

GO Terms for Lichen Planus

Cellular components related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 TNF KRT10 KRT1 IL6 IFNG DEFB4A
2 extracellular space GO:0005615 9.85 TNF KRT10 KRT1 IL6 IFNG ICAM1
3 intermediate filament GO:0005882 9.43 KRT16 KRT13 KRT10 KRT1 FLG DST
4 hemidesmosome GO:0030056 9.26 DST COL17A1
5 cornified envelope GO:0001533 9.02 KRT10 KRT1 IVL FLG DSG3

Biological processes related to Lichen Planus according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.91 TNF ITGAL ICAM1 COL17A1
2 defense response to virus GO:0051607 9.87 MX1 IL6 IFNG CXCL9
3 immune response GO:0006955 9.87 TNF IL6 IFNG DEFB4A CXCR3 CXCL9
4 chemotaxis GO:0006935 9.85 DEFB4A CXCR3 CXCL9 CXCL8
5 cellular response to lipopolysaccharide GO:0071222 9.83 TNF IL6 ICAM1 CXCL9 CXCL8
6 defense response GO:0006952 9.8 TNF MX1 DEFB4A CXCL9 CXCL8
7 inflammatory response GO:0006954 9.8 TNF KRT16 ITGAL IL6 CXCR3 CXCL9
8 chemokine-mediated signaling pathway GO:0070098 9.77 CXCR3 CXCL9 CXCL8
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 TNF IL6 IFNG
10 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.75 DEFB4A CXCL9 CXCL8
11 humoral immune response GO:0006959 9.73 TNF IL6 IFNG
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 TNF IFNG ICAM1
13 keratinocyte differentiation GO:0030216 9.67 KRT16 KRT10 IVL FLG
14 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6
15 establishment of skin barrier GO:0061436 9.63 KRT16 KRT1 FLG
16 keratinization GO:0031424 9.63 KRT16 KRT13 KRT10 KRT1 IVL DSG3
17 hemidesmosome assembly GO:0031581 9.62 DST COL17A1
18 positive regulation of chemokine biosynthetic process GO:0045080 9.62 TNF IFNG
19 negative regulation of amyloid-beta clearance GO:1900222 9.61 TNF IFNG
20 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
21 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell GO:0002291 9.52 ITGAL ICAM1
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IFNG
23 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 TNF IFNG
24 positive regulation of nitrogen compound metabolic process GO:0051173 9.48 TNF IFNG
25 peptide cross-linking GO:0018149 9.26 KRT10 KRT1 IVL FLG
26 cornification GO:0070268 9.17 KRT16 KRT13 KRT10 KRT1 IVL FLG

Molecular functions related to Lichen Planus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 TNF MX1 KRT16 KRT13 KRT10 KRT1
2 structural molecule activity GO:0005198 9.56 KRT16 KRT13 KRT10 FLG
3 cytokine activity GO:0005125 9.35 TNF IL6 IFNG CXCL9 CXCL8
4 structural constituent of epidermis GO:0030280 8.8 KRT10 KRT1 FLG

Sources for Lichen Planus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....